316 related articles for article (PubMed ID: 11438838)
1. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
2. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
3. Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV.
Cordelier P; Strayer DS
Gene Ther; 2003 Dec; 10(26):2153-6. PubMed ID: 14625571
[TBL] [Abstract][Full Text] [Related]
4. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
6. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat.
Robinson D; Elliott JF; Chang LJ
Gene Ther; 1995 Jun; 2(4):269-78. PubMed ID: 7552987
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies.
Mukhtar M; Duan L; Bagasra O; Pomerantz RJ
Gene Ther; 1996 Aug; 3(8):725-30. PubMed ID: 8854098
[TBL] [Abstract][Full Text] [Related]
8. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
10. Antitat gene therapy: a candidate for late-stage AIDS patients.
Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
Li Y; Starr SE; Lisziewicz J; Ho WZ
Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
[TBL] [Abstract][Full Text] [Related]
12. Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag.
Lori F; Lisziewicz J; Smythe J; Cara A; Bunnag TA; Curiel D; Gallo RC
Gene Ther; 1994 Jan; 1(1):27-31. PubMed ID: 7584056
[TBL] [Abstract][Full Text] [Related]
13. Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.
Strayer DS; Pomerantz RJ; Yu M; Rosenzweig M; BouHamdan M; Yurasov S; Johnson RP; Goldstein H
Gene Ther; 2000 May; 7(10):886-95. PubMed ID: 10845727
[TBL] [Abstract][Full Text] [Related]
14. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
15. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication.
Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG
Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513
[TBL] [Abstract][Full Text] [Related]
16. Development of replicative and nonreplicative hepatitis B virus vectors.
Chaisomchit S; Tyrrell DL; Chang LJ
Gene Ther; 1997 Dec; 4(12):1330-40. PubMed ID: 9472557
[TBL] [Abstract][Full Text] [Related]
17. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.
Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E
Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703
[TBL] [Abstract][Full Text] [Related]
18. Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes.
Parolin C; Taddeo B; Palú G; Sodroski J
Virology; 1996 Aug; 222(2):415-22. PubMed ID: 8806525
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters.
Dupuy FP; Mouly E; Mesel-Lemoine M; Morel C; Abriol J; Cherai M; Baillou C; Nègre D; Cosset FL; Klatzmann D; Lemoine FM
J Gene Med; 2005 Sep; 7(9):1158-71. PubMed ID: 15880619
[TBL] [Abstract][Full Text] [Related]
20. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.
Chadwick DR; Lever AM
Gene Ther; 2000 Aug; 7(16):1362-8. PubMed ID: 10981662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
